Antibodies for
Immunohistochemistry
Uroplakin III (AU-1)
Mouse Monoclonal Antibody
Cat. No. Description
Volume
45691 IMPATH Uroplakin III RTU M (AU-1)
50 Tests
44406 Uroplakin RTU M (AU-1)
7 ml Ready To Use
44831 Uroplakin 0,1 M (AU-1)
100 µl liquid Concentrated
44832 Uroplakin 1 M (AU-1)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Cytoplasmic, Membranous
Control
Bladder
Stability
Up to 36 mo. at 2-8°C
Isotype
IgG
1
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
ImPath Protocol*
• Dewax: Dewax Solution 2 (DS2)
• Pretreatment: Retrieval Solution pH 9.0
(TR1) 32min @ 98-103°C
• Primary Antibody Incubation Time:
10-90min @ 25-37°C
• HRP 2-step Polymer (Universal) or AP
Polymer (Universal) for 12 min
*Please refer to product insert for complete protocol.
Product Description
Uroplakins (UPs) are a family of transmembrane proteins (UPs Ia, Ib, II and III) that are specific differentiation products of urothelial cells. In non-
neoplastic mammalian urothelium, UPs are expressed in the luminal surface plasmalemma of superficial (umbrella) cells, forming complexes
of 16 nm crystalline particles. Moll et al. reported that UPIII was detectable immunohistochemically in 29 of 55 primary (53%) and 23 of 35
metastatic (66%) urothelial carcinomas, whereas many non-urothelial carcinomas were UPIII-negative. The authors concluded that anti-UPIII
should be a valuable marker, especially for the specific identification of urothelial carcinomas in patients with metastases of unknown primary
site. Subsequently, Olsburgh et al. studied UP gene expression in normal urothelium and bladder cancer specimens, and found that expression
was absent after malignant transformation. Ohtsuka et al. concluded in their studies that UPIII expression was strongly associated with lower
tumor grades, that lack of UPIII expression in urothelial tumors of the upper urinary tract was associated with much higher rates of metastases,
and that five-year specific survival was much worse for UPIII negative tumors (54%) than for UPIII positive tumors (100%). Apparently UPIII
expression is a better indicator of the malignant potential of the tumor than the grade of the tumor.
Squamous vs. Transitional Carcinoma
Uroplakin III
CK, 34βE12
p63
CK 5
Thrombo-
modulin
CK 7
CK 20
Squamous Carcinoma
-
+
+
+
+
-
-
Transitional Cell Carcinoma
+
+
+
-/+
+
+
+
Prostate Lesions
Uroplakin III
PSA/PSAP P504s
CK, 34βE12
p63
CK 7
Thrombo-
modulin
PAX-2
Prostate Carcinoma
-
+
+
-
-
-
-
-
Urothelial Carcinoma
+
-
-
+
+
+
+
-
Nephrogenic Adenoma
-
-
+
+/-
-
+
-
+
Reference
1. Badalament RA, et al. J Urol. 1990; 144:859–63
2. Hall MC, et al. Urology. 1998; 52:594–601.
3. Logani S, et al. Am J Surg Pathol. 2003 Nov; 27(11):1434-41.
4. Moll R, et al. Am J Pathol. 1995; 147:1383–97.
5. Ohtsuka Y, et al. BJU Int. 2006 Jun; 97(6):1322-6.
6. Olsburgh J, et al. J Pathol. 2003; 199:41–9.
236
